Skip to Main Content

Clinical Studies and Protocols

Site Map Investigators Log-in
(JKR-0937) Secukinumab in Mild Psoriasis

 Return to List of Clinical Studies
 Return to List of Protocols for Psoriasis and Skin Diseases
Safety and Efficacy of Secukinumab in Adults with Chronic Plaque Type Psoriasis with a PASI score of 6 to 12

Principal Investigator:
James G. Krueger M.D., Ph.D.


Contact Information:
Recruitment Specialist
1230 York Ave
New York , NY 10065
Telephone: 1(800)782-2737
Enrollment Status:
Open to Enrollment

Brief Summary of Protocol:
Mild psoriasis not only progresses to moderate-to-severe psoriasis but also precedes systemic inflammation that leads to psoriatic arthritis and cardiovascular comorbidities. By curing mild psoriasis with a short-term anti-IL-17A treatment, we may reduce the costs of treating psoriasis and associated medical conditions, including psoriatic arthritis, cardiovascular disease, and diabetes.

Detailed Description of Protocol:

What specifically makes a person eligible for the study?
You may be eligible to enter this study:

• Blood tests • Skin biopsies • Receipt of the study medication


At least 18 years old

Children permitted to participate:

Potential Benefits.....

Compensation is provided